Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Diabetes

Journal Scan / Research · May 07, 2022

Monotherapy vs Combined Therapy With CD4 + CD25highCD127- T Regulatory Cells and Anti-CD20 Antibody in Recent-Onset T1D

Diabetes, Obesity & Metabolism


Additional Info

Diabetes, Obesity & Metabolism
Combined therapy with CD4 + CD25highCD127- T regulatory cells and anti-CD20 antibody in recent-onset type 1 diabetes is superior to monotherapy — randomized phase I/II trial
Diabetes Obes Metab 2022 Apr 19;[EPub Ahead of Print], M Zieliński, M Żalińska, D Iwaszkiewicz-Grześ, M Gliwiński, M Hennig, A Jaźwińska-Curyłło, H Kamińska, J Sakowska, A Wołoszyn-Durkiewicz, R Owczuk, W Młynarski, P Jarosz-Chobot, A Bossowski, A Szadkowska, J Siebert, M Myśliwiec, N Marek-Trzonkowska, P Trzonkowski

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading